Paper6413638
Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.
Grimm EA and 6 others. J Exp Med, 1983. Cited by 468 papers, by iCite.
Cite this record
ConductScience Library. Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells. Papers, record 6413638. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6413638
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Interleukin-2 | Major topic |
| Killer Cells, Natural | Major topic |
| Lymphocyte Activation | Major topic |
| Antibodies, Monoclonal | |
| Binding, Competitive | |
| Humans | |
| Lymphocytes | |
| Phenotype | |
| Receptors, Immunologic | |
| Receptors, Interleukin-2 | |
| Stem Cells |
Source PubMed
References13
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 1087116 | Identification of T cell lymphoma tumor antigens on human T cell lines. | Am J Hematol | 1976 | https://conductscience.org/library/papers/1087116 | PubMed |
| 2 | 6966652 | In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. | J Immunol | 1980 | https://conductscience.org/library/papers/6966652 | PubMed |
| 3 | 6778951 | Biochemical and biological characterization of lymphocyte regulatory molecules. V. Identification of an interleukin 2-producing human leukemia T cell line. | J Exp Med | 1980 | https://conductscience.org/library/papers/6778951 | PubMed |
| 4 | 6970774 | A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. | J Immunol | 1981 | https://conductscience.org/library/papers/6970774 | PubMed |
| 5 | 6453159 | In vitro growth of cytotoxic human lymphocytes. III. The preparation of lectin-free T cell growth factor (TCGF) and an analysis of its activity. | J Immunol | 1981 | https://conductscience.org/library/papers/6453159 | PubMed |
| 6 | 6785531 | Purification of human interleukin 1. | J Supramol Struct | 1980 | https://conductscience.org/library/papers/6785531 | PubMed |
| 7 | 6975300 | Spontaneous release of a factor with properties of T cell growth factor from a continuous line of primate tumor T cells. | J Immunol | 1981 | https://conductscience.org/library/papers/6975300 | PubMed |
| 8 | 6975347 | T cell growth factor receptors. Quantitation, specificity, and biological relevance. | J Exp Med | 1981 | https://conductscience.org/library/papers/6975347 | PubMed |
| 9 | 6975652 | Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. | Cancer Res | 1981 | https://conductscience.org/library/papers/6975652 | PubMed |
| 10 | 6976987 | The purification and properties of human T cell growth factor. | J Immunol | 1982 | https://conductscience.org/library/papers/6976987 | PubMed |
| 11 | 6176669 | Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. | J Exp Med | 1982 | https://conductscience.org/library/papers/6176669 | PubMed |
| 12 | 7047366 | Human T-cell growth factor: purification biochemical characterization, and interaction with a cellular receptor. | Immunobiology | 1982 | https://conductscience.org/library/papers/7047366 | PubMed |
| 13 | 6815536 | A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor. | Nature | 1982 | https://conductscience.org/library/papers/6815536 | PubMed |
Cited by78
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 468 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41135520 | Engineered natural killer cells for cancer therapy. | Cancer Cell | 2025 | https://conductscience.org/library/papers/41135520 | PubMed |
| 37218360 | Inhibiting N-glycan processing increases the antibody binding affinity and effector function of human natural killer cells. | Immunology | 2023 | https://conductscience.org/library/papers/37218360 | PubMed |
| 36588388 | Advanced T and Natural Killer Cell Therapy for Glioblastoma. | J Korean Neurosurg Soc | 2023 | https://conductscience.org/library/papers/36588388 | PubMed |
| 35720306 | Next Generation Natural Killer Cells for Cancer Immunotherapy. | Front Immunol | 2022 | https://conductscience.org/library/papers/35720306 | PubMed |
| 34169631 | There and back again: Translating adoptive cell therapy to canine cancer and improving human treatment. | Vet Comp Oncol | 2021 | https://conductscience.org/library/papers/34169631 | PubMed |
| 31907401 | NK cells for cancer immunotherapy. | Nat Rev Drug Discov | 2020 | https://conductscience.org/library/papers/31907401 | PubMed |
| 31798595 | CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy. | Front Immunol | 2019 | https://conductscience.org/library/papers/31798595 | PubMed |
| 28545888 | Delivering safer immunotherapies for cancer. | Adv Drug Deliv Rev | 2017 | https://conductscience.org/library/papers/28545888 | PubMed |
| 27372731 | Chimeric antigen receptors: driving immunology towards synthetic biology. | Curr Opin Immunol | 2016 | https://conductscience.org/library/papers/27372731 | PubMed |
| 24376448 | Regulation of mouse NK cell development and function by cytokines. | Front Immunol | 2013 | https://conductscience.org/library/papers/24376448 | PubMed |
| 22027907 | IL-2 regulates the expression of the tumor suppressor IL-24 in melanoma cells. | Melanoma Res | 2012 | https://conductscience.org/library/papers/22027907 | PubMed |
| 21716670 | Role of common-gamma chain cytokines in NK cell development and function: perspectives for immunotherapy. | J Biomed Biotechnol | 2011 | https://conductscience.org/library/papers/21716670 | PubMed |
| 21487512 | Comparative analysis of NK-cell receptor expression and function across primate species: Perspective on antiviral defenses. | Self Nonself | 2010 | https://conductscience.org/library/papers/21487512 | PubMed |
| 21432415 | Cigarette smoking is associated with the reduction of lymphokine-activated killer cell and natural killer cell activities. | Environ Health Prev Med | 1996 | https://conductscience.org/library/papers/21432415 | PubMed |
| 20734041 | Identification and characterization of a tumor infiltrating CD56(+)/CD16 (-) NK cell subset with specificity for pancreatic and prostate cancer cell lines. | Cancer Immunol Immunother | 2010 | https://conductscience.org/library/papers/20734041 | PubMed |
| 20237297 | Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice. | J Immunol | 2010 | https://conductscience.org/library/papers/20237297 | PubMed |
| 15693143 | Natural killer (NK) and lymphokine-activated killer (LAK) cell functions from healthy dogs and 29 dogs with a variety of spontaneous neoplasms. | Cancer Immunol Immunother | 2005 | https://conductscience.org/library/papers/15693143 | PubMed |
| 10815620 | Killer-cell inhibitory receptors, CD158a/b, are upregulated by interleukin-2, but not interferon-gamma or interleukin-4. | Mediators Inflamm | 1999 | https://conductscience.org/library/papers/10815620 | PubMed |
| 9659223 | Differential cytokine regulation of natural killer cell-mediated necrotic and apoptotic cytotoxicity. | Immunology | 1998 | https://conductscience.org/library/papers/9659223 | PubMed |
| 9617349 | Enhancement of anti-tumor activity of natural killer cells by BALL-1, a B cell lymphoma line. | Jpn J Cancer Res | 1998 | https://conductscience.org/library/papers/9617349 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| IL2 | 3558 | PubTator's text mining | https://conductscience.org/library/genes/3558 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6413638
GET https://conductscience.org/api/papers/v1/6413638/cited_by?page=2